组织驻留记忆T细胞在实体瘤治疗中的研究进展

Research progress in the therapeutic application of tissue-resident memory T cells in solid tumors

血液循环中存在大量的免疫细胞,它们能够阻止病原微生物的感染和入侵,并在肿瘤防治中发挥重要作用。组织驻留记忆T细胞(TRM)是一个特殊的肿瘤浸润淋巴细胞亚群,能够无限期地驻留在组织中,对其同源抗原作出快速的免疫应答。TRM包括CD4^(+)和CD8^(+)两个亚群,均以表达CD69和CD103标记物为主要特征,通过产生杀伤性细胞因子等方式,激活固有免疫和适应性免疫应答。TRM在减缓肿瘤发生发展、抑制转移和降低肿瘤复发等方面的作用已在多种实体瘤中得到证实。为深入研究这些细胞的生物学特性和免疫机制,在查阅文献的基础上,梳理组织驻留记忆T细胞的基本生物学特征,综述CD8^(+)TRM细胞在乳腺癌、非小细胞肺癌和肝癌等实体瘤治疗中的作用和研究进展,旨在为肿瘤治疗提供新的策略和靶点。

There are a large number of immune cells in the blood circulation,which are capable of preventing infection and invasion by pathogenic microorganisms and also play an important role in tumor progression.Tissueresident momory T cells(TRM)are a special subset of tumor infiltrating lymphocytes that can indefinitely reside in tissues and respond rapidly to their homologous antigens.TRM consists of two subgroups,CD4^(+)and CD8^(+),both characterized by the expression of CD69 and CD103 markers,which activate innate and adaptive immune responses through the production of cytotoxic cytokines.The role of TRM in slowing down tumor occurrence and development,inhibiting metastasis,and reducing tumor recurrence has been confirmed in various solid tumors.In order to further investigate the biological characteristics and immune mechanism of these cells,based on literature review,the basic biological characteristics of tissue resident memory T cells were combed,and the role and research progress of CD8^(+)TRM cells in the treatment of solid tumors such as breast cancer,non-small cell lung cancer and liver cancer were reviewed,aiming to provide new strategies and targets for tumor treatment.